These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 24699033)

  • 1. The ebbs and flows in the development of cholesterol-lowering drugs: prospects for the future.
    Hajhosseiny R; Sabir I; Khavandi K; Wierzbicki AS
    Clin Pharmacol Ther; 2014 Jul; 96(1):64-73. PubMed ID: 24699033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future.
    Stein EA; Raal FJ
    Curr Cardiol Rep; 2015 Nov; 17(11):104. PubMed ID: 26385394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New therapies to reduce low-density lipoprotein cholesterol.
    Wierzbicki AS; Viljoen A; Hardman TC; Mikhailidis DP
    Curr Opin Cardiol; 2013 Jul; 28(4):452-7. PubMed ID: 23736819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel strategies for managing dyslipidemia: treatment beyond statins.
    Ling H; Burns TL; Hilleman DE
    Postgrad Med; 2012 Nov; 124(6):43-54. PubMed ID: 23322138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].
    Bajnok L
    Orv Hetil; 2014 Jan; 155(2):62-8. PubMed ID: 24389322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
    Dragan S; Serban MC; Banach M
    J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):157-68. PubMed ID: 24938457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Other therapies for reducing low-density lipoprotein cholesterol: medications in development.
    Stein EA
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):99-119. PubMed ID: 19217514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Lipid control in high-risk patients: focus on PCSK9 inhibitors].
    Filardi PP; Paolillo S; Trimarco B
    G Ital Cardiol (Rome); 2015 Jan; 16(1):44-51. PubMed ID: 25689751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-density lipoprotein cholesterol lowering therapies: what is on the horizon?
    Gadi R; Figueredo VM
    J Cardiovasc Med (Hagerstown); 2015 Jan; 16(1):1-10. PubMed ID: 25379719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel therapeutic agents for lowering low density lipoprotein cholesterol.
    Joy TR
    Pharmacol Ther; 2012 Jul; 135(1):31-43. PubMed ID: 22465160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy and clinical trials.
    Sodhi N; Krasuski RA
    Curr Opin Lipidol; 2013 Jun; 24(3):281-2. PubMed ID: 23652475
    [No Abstract]   [Full Text] [Related]  

  • 14. Winner by points?--LDL cholesterol as a target for therapeutic intervention.
    Tietge UJ
    Curr Opin Lipidol; 2013 Jun; 24(3):277-8. PubMed ID: 23652473
    [No Abstract]   [Full Text] [Related]  

  • 15. Familial hypercholesterolemia: present and future management.
    Sjouke B; Kusters DM; Kastelein JJ; Hovingh GK
    Curr Cardiol Rep; 2011 Dec; 13(6):527-36. PubMed ID: 21938413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dyslipidaemia: what's around the corner?
    Wierzbicki AS; Perera D; Ewang-Emukowhate M
    Clin Med (Lond); 2014 Dec; 14 Suppl 6():s41-4. PubMed ID: 25468918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New lipid-lowering drugs: an update.
    Wierzbicki AS; Hardman TC; Viljoen A
    Int J Clin Pract; 2012 Mar; 66(3):270-80. PubMed ID: 22340447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How far down to push the LDL cholesterol? PCSK9 where statins fail.
    Simko V; Ginter E
    Bratisl Lek Listy; 2016; 117(4):193-4. PubMed ID: 27075380
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination therapy in dyslipidemia: where are we now?
    Catapano AL; Farnier M; Foody JM; Toth PP; Tomassini JE; Brudi P; Tershakovec AM
    Atherosclerosis; 2014 Nov; 237(1):319-35. PubMed ID: 25299967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PCSK9 inhibitors.
    Farnier M
    Curr Opin Lipidol; 2013 Jun; 24(3):251-8. PubMed ID: 23652470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.